Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Sorafenib in Treating Patients With Metastatic Breast Cancer

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Male Breast Cancer

Recurrent Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This phase II trial is studying how well sorafenib works in treating patients with metastatic breast cancer. Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their gr...

Detailed Description

OBJECTIVES: I. Determine the tumor response rate in patients with metastatic breast cancer previously treated with an anthracycline- and/or taxane-containing regimen receiving sorafenib. II. Assess ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Histologically or cytologically confirmed breast cancer
  • Clinical evidence of metastatic disease
  • Measurable disease
  • HER2-positive or -negative disease
  • If HER2 gene amplified or strongly positive for HER2 by immunohistochemistry, patient must have had prior treatment containing trastuzumab (Herceptin®) unless contraindicated
  • Previously treated with anthracycline- and/or taxane-containing regimen in the neoadjuvant, adjuvant, or metastatic setting
  • Candidate for first- or second-line chemotherapy for metastatic disease
  • Core block or tumor slides of the primary or metastatic tumor available
  • No known brain metastases
  • Hormone receptor status:
  • Not specified
  • Male or female
  • Performance status - ECOG 0-1
  • At least 3 months
  • WBC ≥ 3,000/mm\^3
  • Absolute neutrophil count ≥ 1,500/mm\^3
  • Platelet count ≥ 100,000/mm\^3
  • Hemoglobin ≥ 8.5 g/dL
  • No evidence of bleeding diathesis
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST ≤ 3 times ULN
  • Alkaline phosphatase ≤ 3 times ULN
  • PT normal
  • PTT normal
  • INR normal
  • Creatinine ≤ 1.5 times ULN
  • Calcium normal
  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • No uncontrolled hypertension
  • No gastrointestinal tract disease that would preclude taking oral medication
  • No active peptic ulcer disease
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer
  • No history of allergic reaction attributed to compounds of similar chemical or biological composition to sorafenib or other study agents
  • No ongoing or active infection
  • No psychiatric illness or social situation that would preclude study participation
  • No other uncontrolled illness
  • See Disease Characteristics
  • More than 4 weeks since prior immunotherapy
  • No concurrent anticancer immunotherapy
  • No concurrent bevacizumab
  • See Disease Characteristics
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
  • No more than 1 prior chemotherapy regimen for metastatic disease
  • No concurrent anticancer chemotherapy
  • Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting is allowed
  • No concurrent anticancer hormonal therapy
  • No prior radiotherapy to ≥ 25% of the bone marrow
  • More than 4 weeks since prior radiotherapy
  • More than 4 weeks since prior major surgery
  • No prior surgical procedure that would affect gastrointestinal absorption
  • No other concurrent drugs that target vascular endothelial growth factor (VEGF) or VEGF receptors
  • No concurrent antiretroviral therapy for HIV-positive patients
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy
  • No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs, including any of the following:
  • Phenytoin
  • Carbamazepine
  • Phenobarbital
  • No concurrent rifampin
  • No concurrent Hypericum perforatum (St. John's wort)
  • No concurrent therapeutic anticoagulation
  • Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial devices is allowed

Exclusion

    Key Trial Info

    Start Date :

    September 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    23 Patients enrolled

    Trial Details

    Trial ID

    NCT00096434

    Start Date

    September 1 2004

    Last Update

    March 7 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    North Central Cancer Treatment Group

    Rochester, Minnesota, United States, 55905